MKI67 and neoplasm: With respect to patients with stage II–III (locally advanced) NSCLCs, the 5-year survival rate of patients with low Ki-67 tumours was significantly higher than that of patients with high Ki-67 tumours (43.2 vs 20.0%, P=0.02, Figure 2A).